Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1849 to 1860 of 1876 entries
Sorted by: Best Match Show Resources per page
Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study.

Drugs - real world outcomes

Fung KW, Baye F, Kapusnik-Uner J, McDonald CJ.
PMID: 33569737
Drugs Real World Outcomes. 2021 Jun;8(2):173-185. doi: 10.1007/s40801-021-00230-1. Epub 2021 Feb 10.

INTRODUCTION: Serious cardiac arrhythmias caused by QT-prolonging drugs are difficult to predict based on physiological measurement and pre-approval clinical trials. Post-marketing surveillance and monitoring are important to generate safety data.OBJECTIVES: To assess whether an observational study using Medicare claims...

Cite
Fung KW, Baye F, Kapusnik-Uner J, et al. Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study. Drugs Real World Outcomes. 2021;8(2):173-185doi: 10.1007/s40801-021-00230-1.
Fung, K. W., Baye, F., Kapusnik-Uner, J., & McDonald, C. J. (2021). Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study. Drugs - real world outcomes, 8(2), 173-185. https://doi.org/10.1007/s40801-021-00230-1
Fung, Kin Wah, et al. "Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study." Drugs - real world outcomes vol. 8,2 (2021): 173-185. doi: https://doi.org/10.1007/s40801-021-00230-1
Fung KW, Baye F, Kapusnik-Uner J, McDonald CJ. Using Medicare Data to Assess the Proarrhythmic Risk of Non-Cardiac Treatment Drugs that Prolong the QT Interval in Older Adults: An Observational Cohort Study. Drugs Real World Outcomes. 2021 Jun;8(2):173-185. doi: 10.1007/s40801-021-00230-1. Epub 2021 Feb 10. PMID: 33569737; PMCID: PMC7875170.
Copy Download .nbib Format: NLM
Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children.

Journal of the Formosan Medical Association = Taiwan yi zhi

Su DJ, Chang MH, Yang JC, Ni YH, Hsu HY, Wu JF.
PMID: 33745813
J Formos Med Assoc. 2021 Mar 18; doi: 10.1016/j.jfma.2021.03.001. Epub 2021 Mar 18.

BACKGROUND/PURPOSE: Helicobacter pylori infection is one of the most common causes of peptic ulcer disease among children. This study is aimed to investigate the eradication rate of 14-day sequential therapy and the antibiotic resistance of H. pylori in children.METHODS:...

Cite
Su DJ, Chang MH, Yang JC, et al. Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children. J Formos Med Assoc. 2021;doi: 10.1016/j.jfma.2021.03.001.
Su, D. J., Chang, M. H., Yang, J. C., Ni, Y. H., Hsu, H. Y., & Wu, J. F. (2021). Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children. Journal of the Formosan Medical Association = Taiwan yi zhi, . https://doi.org/10.1016/j.jfma.2021.03.001
Su, Da-Jyun, et al. "Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children." Journal of the Formosan Medical Association = Taiwan yi zhi vol. (2021). doi: https://doi.org/10.1016/j.jfma.2021.03.001
Su DJ, Chang MH, Yang JC, Ni YH, Hsu HY, Wu JF. Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children. J Formos Med Assoc. 2021 Mar 18; doi: 10.1016/j.jfma.2021.03.001. Epub 2021 Mar 18. PMID: 33745813.
Copy Download .nbib Format: NLM
Residual β-lactam antibiotics and ecotoxicity to Vibrio fischeri, Daphnia magna of pharmaceutical wastewater in the treatment process.

Journal of hazardous materials

Hu Y, Lei D, Wu D, Xia J, Zhou W, Cui C.
PMID: 34896711
J Hazard Mater. 2021 Nov 22;425:127840. doi: 10.1016/j.jhazmat.2021.127840. Epub 2021 Nov 22.

The discharge of pharmaceutical wastewater introduces numerous pollutants into the environment, and their pollution level reduction has aroused extensive concern. This study investigated the variation in residual antibiotics and ecotoxicity to two nutritional-level model organisms in the pharmaceutical wastewater...

Cite
Hu Y, Lei D, Wu D, et al. Residual β-lactam antibiotics and ecotoxicity to Vibrio fischeri, Daphnia magna of pharmaceutical wastewater in the treatment process. J Hazard Mater. 2021;425:127840doi: 10.1016/j.jhazmat.2021.127840.
Hu, Y., Lei, D., Wu, D., Xia, J., Zhou, W., & Cui, C. (2021). Residual β-lactam antibiotics and ecotoxicity to Vibrio fischeri, Daphnia magna of pharmaceutical wastewater in the treatment process. Journal of hazardous materials, 425127840. https://doi.org/10.1016/j.jhazmat.2021.127840
Hu, Yaru, et al. "Residual β-lactam antibiotics and ecotoxicity to Vibrio fischeri, Daphnia magna of pharmaceutical wastewater in the treatment process." Journal of hazardous materials vol. 425 (2021): 127840. doi: https://doi.org/10.1016/j.jhazmat.2021.127840
Hu Y, Lei D, Wu D, Xia J, Zhou W, Cui C. Residual β-lactam antibiotics and ecotoxicity to Vibrio fischeri, Daphnia magna of pharmaceutical wastewater in the treatment process. J Hazard Mater. 2021 Nov 22;425:127840. doi: 10.1016/j.jhazmat.2021.127840. Epub 2021 Nov 22. PMID: 34896711.
Copy Download .nbib Format: NLM
Risk of antibiotic treatment failure in premenopausal women with uncomplicated urinary tract infection.

Pharmacoepidemiology and drug safety

Butler AM, Durkin MJ, Keller MR, Ma Y, Dharnidharka VR, Powderly WG, Olsen MA.
PMID: 33783918
Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1360-1370. doi: 10.1002/pds.5237. Epub 2021 Apr 13.

PURPOSE: Acute uncomplicated urinary tract infections (UTIs) are among the most common indications for antibiotic prescriptions in otherwise healthy women. We compared the risk of treatment failure of antibiotic regimens for outpatient treatment of UTI in real-world practice.METHODS: We...

Cite
Butler AM, Durkin MJ, Keller MR, et al. Risk of antibiotic treatment failure in premenopausal women with uncomplicated urinary tract infection. Pharmacoepidemiol Drug Saf. 2021;30(10):1360-1370doi: 10.1002/pds.5237.
Butler, A. M., Durkin, M. J., Keller, M. R., Ma, Y., Dharnidharka, V. R., Powderly, W. G., & Olsen, M. A. (2021). Risk of antibiotic treatment failure in premenopausal women with uncomplicated urinary tract infection. Pharmacoepidemiology and drug safety, 30(10), 1360-1370. https://doi.org/10.1002/pds.5237
Butler, Anne M, et al. "Risk of antibiotic treatment failure in premenopausal women with uncomplicated urinary tract infection." Pharmacoepidemiology and drug safety vol. 30,10 (2021): 1360-1370. doi: https://doi.org/10.1002/pds.5237
Butler AM, Durkin MJ, Keller MR, Ma Y, Dharnidharka VR, Powderly WG, Olsen MA. Risk of antibiotic treatment failure in premenopausal women with uncomplicated urinary tract infection. Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1360-1370. doi: 10.1002/pds.5237. Epub 2021 Apr 13. PMID: 33783918; PMCID: PMC8419150.
Copy Download .nbib Format: NLM
Comparative Assessment of the Antimicrobial Efficacy of Triclosan, Amoxicillin and Eugenol against .

International journal of clinical pediatric dentistry

Gowda J, Tavarageri A, Kulkarni R, Anegundi RT, Janardhan A, Bhat MA.
PMID: 34326585
Int J Clin Pediatr Dent. 2021 Jan-Feb;14(1):59-62. doi: 10.5005/jp-journals-10005-1869.

AIMS: Elimination of microorganisms and prevention of recurrence of infection from the complex root canal system of primary teeth requires an obturating material with broad antimicrobial activity. Hence, the purpose of the study is to assess and compare the...

Cite
Gowda J, Tavarageri A, Kulkarni R, et al. Comparative Assessment of the Antimicrobial Efficacy of Triclosan, Amoxicillin and Eugenol against . Int J Clin Pediatr Dent. 2021;14(1):59-62doi: 10.5005/jp-journals-10005-1869.
Gowda, J., Tavarageri, A., Kulkarni, R., Anegundi, R. T., Janardhan, A., & Bhat, M. A. (2021). Comparative Assessment of the Antimicrobial Efficacy of Triclosan, Amoxicillin and Eugenol against . International journal of clinical pediatric dentistry, 14(1), 59-62. https://doi.org/10.5005/jp-journals-10005-1869
Gowda, Jagadish, et al. "Comparative Assessment of the Antimicrobial Efficacy of Triclosan, Amoxicillin and Eugenol against ." International journal of clinical pediatric dentistry vol. 14,1 (2021): 59-62. doi: https://doi.org/10.5005/jp-journals-10005-1869
Gowda J, Tavarageri A, Kulkarni R, Anegundi RT, Janardhan A, Bhat MA. Comparative Assessment of the Antimicrobial Efficacy of Triclosan, Amoxicillin and Eugenol against . Int J Clin Pediatr Dent. 2021 Jan-Feb;14(1):59-62. doi: 10.5005/jp-journals-10005-1869. PMID: 34326585; PMCID: PMC8311773.
Copy Download .nbib Format: NLM
Self-Assembled Nanoparticles of Natural Phytochemicals (Berberine and 3,4,5-Methoxycinnamic Acid) Originated from Traditional Chinese Medicine for Inhibiting Multidrug-Resistant Staphylococcus aureus.

Current drug delivery

Han N, Huang X, Tian X, Li T, Liu X, Li W, Huo S, Wu Q, Gu Y, Dai Z, Xu B, Wang P, Lei H.
PMID: 33234104
Curr Drug Deliv. 2021;18(7):914-921. doi: 10.2174/1567201817666201124121918.

BACKGROUND: In the field of antibacterial, nanomaterials are favored by researchers because of their unique advantages. Medicinal plants, especially traditional Chinese medicine, are considered to be an important source of new chemicals with potential therapeutic effects, as well as...

Cite
Han N, Huang X, Tian X, et al. Self-Assembled Nanoparticles of Natural Phytochemicals (Berberine and 3,4,5-Methoxycinnamic Acid) Originated from Traditional Chinese Medicine for Inhibiting Multidrug-Resistant Staphylococcus aureus. Curr Drug Deliv. 2021;18(7):914-921doi: 10.2174/1567201817666201124121918.
Han, N., Huang, X., Tian, X., Li, T., Liu, X., Li, W., Huo, S., Wu, Q., Gu, Y., Dai, Z., Xu, B., Wang, P., & Lei, H. (2021). Self-Assembled Nanoparticles of Natural Phytochemicals (Berberine and 3,4,5-Methoxycinnamic Acid) Originated from Traditional Chinese Medicine for Inhibiting Multidrug-Resistant Staphylococcus aureus. Current drug delivery, 18(7), 914-921. https://doi.org/10.2174/1567201817666201124121918
Han, Nana, et al. "Self-Assembled Nanoparticles of Natural Phytochemicals (Berberine and 3,4,5-Methoxycinnamic Acid) Originated from Traditional Chinese Medicine for Inhibiting Multidrug-Resistant Staphylococcus aureus." Current drug delivery vol. 18,7 (2021): 914-921. doi: https://doi.org/10.2174/1567201817666201124121918
Han N, Huang X, Tian X, Li T, Liu X, Li W, Huo S, Wu Q, Gu Y, Dai Z, Xu B, Wang P, Lei H. Self-Assembled Nanoparticles of Natural Phytochemicals (Berberine and 3,4,5-Methoxycinnamic Acid) Originated from Traditional Chinese Medicine for Inhibiting Multidrug-Resistant Staphylococcus aureus. Curr Drug Deliv. 2021;18(7):914-921. doi: 10.2174/1567201817666201124121918. PMID: 33234104.
Copy Download .nbib Format: NLM
Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study.

Clinical and translational gastroenterology

Liu J, Ji CR, Li YY, Qiao C, Hu JN, Wan M, Lin MJ, Lin BS, Wang J, Zha J, Li LX, Zuo XL.
PMID: 34397042
Clin Transl Gastroenterol. 2021 Aug 16;12(8):e00391. doi: 10.14309/ctg.0000000000000391.

INTRODUCTION: We aim to evaluate the efficacy of 2 different 1-week quadruple therapies given back-to-back consecutive therapy in patients with difficult-to-treat Helicobacter pylori infection.METHODS: Patients with proven H. pylori infection were recruited after >3 failed standard quadruple eradication. They...

Cite
Liu J, Ji CR, Li YY, et al. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study. Clin Transl Gastroenterol. 2021;12(8):e00391doi: 10.14309/ctg.0000000000000391.
Liu, J., Ji, C. R., Li, Y. Y., Qiao, C., Hu, J. N., Wan, M., Lin, M. J., Lin, B. S., Wang, J., Zha, J., Li, L. X., & Zuo, X. L. (2021). Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study. Clinical and translational gastroenterology, 12(8), e00391. https://doi.org/10.14309/ctg.0000000000000391
Liu, Jing, et al. "Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study." Clinical and translational gastroenterology vol. 12,8 (2021): e00391. doi: https://doi.org/10.14309/ctg.0000000000000391
Liu J, Ji CR, Li YY, Qiao C, Hu JN, Wan M, Lin MJ, Lin BS, Wang J, Zha J, Li LX, Zuo XL. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study. Clin Transl Gastroenterol. 2021 Aug 16;12(8):e00391. doi: 10.14309/ctg.0000000000000391. PMID: 34397042; PMCID: PMC8373551.
Copy Download .nbib Format: NLM
Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort.

BJOG : an international journal of obstetrics and gynaecology

Lorthe E, Letouzey M, Torchin H, Foix L'Helias L, Gras-Le Guen C, Benhammou V, Boileau P, Charlier C, Kayem G.
PMID: 34954867
BJOG. 2021 Dec 26; doi: 10.1111/1471-0528.17081. Epub 2021 Dec 26.

OBJECTIVE: To compare different antibiotic prophylaxis administered after preterm premature rupture of membranes to determine whether any were associated with differences in obstetric and/or neonatal outcomes and/or neurodevelopmental outcomes at 2 years of corrected age.DESIGN: Prospective, nationwide, population-based EPIPAGE-2...

Cite
Lorthe E, Letouzey M, Torchin H, et al. Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort. BJOG. 2021;doi: 10.1111/1471-0528.17081.
Lorthe, E., Letouzey, M., Torchin, H., Foix L'Helias, L., Gras-Le Guen, C., Benhammou, V., Boileau, P., Charlier, C., Kayem, G. (2021). Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort. BJOG : an international journal of obstetrics and gynaecology, . https://doi.org/10.1111/1471-0528.17081
Lorthe, Elsa, et al. "Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort." BJOG : an international journal of obstetrics and gynaecology vol. (2021). doi: https://doi.org/10.1111/1471-0528.17081
Lorthe E, Letouzey M, Torchin H, Foix L'Helias L, Gras-Le Guen C, Benhammou V, Boileau P, Charlier C, Kayem G. Antibiotic prophylaxis in preterm premature rupture of membranes at 24-31 weeks' gestation: Perinatal and 2-year outcomes in the EPIPAGE-2 cohort. BJOG. 2021 Dec 26; doi: 10.1111/1471-0528.17081. Epub 2021 Dec 26. PMID: 34954867.
Copy Download .nbib Format: NLM
Peritoneal dialysis-related peritonitis caused by Gordonia bronchialis: first pediatric report.

Pediatric nephrology (Berlin, Germany)

Bruno V, Tjon J, Lin S, Groves H, Kazmi K, Zappitelli M, Harvey E.
PMID: 34633526
Pediatr Nephrol. 2022 Jan;37(1):217-220. doi: 10.1007/s00467-021-05313-3. Epub 2021 Oct 11.

INTRODUCTION: Gordonia species, aerobic, weakly acid-fast, Gram-positive bacilli, are a rare cause of peritonitis in patients undergoing peritoneal dialysis (PD). We report the first pediatric case of PD-related peritonitis caused by Gordonia bronchialis.CASE PRESENTATION: A 13-year-old girl with chronic...

Cite
Bruno V, Tjon J, Lin S, et al. Peritoneal dialysis-related peritonitis caused by Gordonia bronchialis: first pediatric report. Pediatr Nephrol. 2021;37(1):217-220doi: 10.1007/s00467-021-05313-3.
Bruno, V., Tjon, J., Lin, S., Groves, H., Kazmi, K., Zappitelli, M., & Harvey, E. (2022). Peritoneal dialysis-related peritonitis caused by Gordonia bronchialis: first pediatric report. Pediatric nephrology (Berlin, Germany), 37(1), 217-220. https://doi.org/10.1007/s00467-021-05313-3
Bruno, Valentina, et al. "Peritoneal dialysis-related peritonitis caused by Gordonia bronchialis: first pediatric report." Pediatric nephrology (Berlin, Germany) vol. 37,1 (2022): 217-220. doi: https://doi.org/10.1007/s00467-021-05313-3
Bruno V, Tjon J, Lin S, Groves H, Kazmi K, Zappitelli M, Harvey E. Peritoneal dialysis-related peritonitis caused by Gordonia bronchialis: first pediatric report. Pediatr Nephrol. 2022 Jan;37(1):217-220. doi: 10.1007/s00467-021-05313-3. Epub 2021 Oct 11. PMID: 34633526; PMCID: PMC8503381.
Copy Download .nbib Format: NLM
Acute Kidney Injury After High Doses of Amoxicillin.

Kidney international reports

Mousseaux C, Rafat C, Letavernier E, Frochot V, Kerroumi Y, Zeller V, Luque Y.
PMID: 33732998
Kidney Int Rep. 2020 Dec 13;6(3):830-834. doi: 10.1016/j.ekir.2020.11.040. eCollection 2021 Mar.

No abstract available.

Cite
Mousseaux C, Rafat C, Letavernier E, et al. Acute Kidney Injury After High Doses of Amoxicillin. Kidney Int Rep. 2020;6(3):830-834doi: 10.1016/j.ekir.2020.11.040.
Mousseaux, C., Rafat, C., Letavernier, E., Frochot, V., Kerroumi, Y., Zeller, V., & Luque, Y. (2021). Acute Kidney Injury After High Doses of Amoxicillin. Kidney international reports, 6(3), 830-834. https://doi.org/10.1016/j.ekir.2020.11.040
Mousseaux, Cyril, et al. "Acute Kidney Injury After High Doses of Amoxicillin." Kidney international reports vol. 6,3 (2021): 830-834. doi: https://doi.org/10.1016/j.ekir.2020.11.040
Mousseaux C, Rafat C, Letavernier E, Frochot V, Kerroumi Y, Zeller V, Luque Y. Acute Kidney Injury After High Doses of Amoxicillin. Kidney Int Rep. 2020 Dec 13;6(3):830-834. doi: 10.1016/j.ekir.2020.11.040. eCollection 2021 Mar. PMID: 33732998; PMCID: PMC7938081.
Copy Download .nbib Format: NLM
Malawian children with fast-breathing pneumonia with and without comorbidities.

Pneumonia (Nathan Qld.)

Ginsburg AS, Mvalo T, Hwang J, Phiri M, McCollum ED, Maliwichi M, Schmicker R, Phiri A, Lufesi N, May S.
PMID: 33627192
Pneumonia (Nathan). 2021 Feb 25;13(1):3. doi: 10.1186/s41479-021-00081-y.

BACKGROUND: Due to high risk of mortality, children with comorbidities are typically excluded from trials evaluating pneumonia treatment. Understanding heterogeneity of outcomes among children with pneumonia and comorbidities is critical to ensuring appropriate treatment.METHODS: We explored whether the percentage...

Cite
Ginsburg AS, Mvalo T, Hwang J, et al. Malawian children with fast-breathing pneumonia with and without comorbidities. Pneumonia (Nathan). 2021;13(1):3doi: 10.1186/s41479-021-00081-y.
Ginsburg, A. S., Mvalo, T., Hwang, J., Phiri, M., McCollum, E. D., Maliwichi, M., Schmicker, R., Phiri, A., Lufesi, N., & May, S. (2021). Malawian children with fast-breathing pneumonia with and without comorbidities. Pneumonia (Nathan Qld.), 13(1), 3. https://doi.org/10.1186/s41479-021-00081-y
Ginsburg, Amy Sarah, et al. "Malawian children with fast-breathing pneumonia with and without comorbidities." Pneumonia (Nathan Qld.) vol. 13,1 (2021): 3. doi: https://doi.org/10.1186/s41479-021-00081-y
Ginsburg AS, Mvalo T, Hwang J, Phiri M, McCollum ED, Maliwichi M, Schmicker R, Phiri A, Lufesi N, May S. Malawian children with fast-breathing pneumonia with and without comorbidities. Pneumonia (Nathan). 2021 Feb 25;13(1):3. doi: 10.1186/s41479-021-00081-y. PMID: 33627192; PMCID: PMC7905626.
Copy Download .nbib Format: NLM
Evidence-Based, Patient-Centered Treatment of Erythema Migrans in the United States.

Antibiotics (Basel, Switzerland)

Maloney EL.
PMID: 34206379
Antibiotics (Basel). 2021 Jun 22;10(7). doi: 10.3390/antibiotics10070754.

Lyme disease, often characterized as a readily treatable infection, can be a debilitating and expensive illness, especially when patients remain symptomatic following therapy for early disease. Identifying and promoting highly effective therapeutic interventions for US patients with erythema migrans...

Cite
Maloney EL. Evidence-Based, Patient-Centered Treatment of Erythema Migrans in the United States. Antibiotics (Basel). 2021;10(7)doi: 10.3390/antibiotics10070754.
Maloney, E. L. (2021). Evidence-Based, Patient-Centered Treatment of Erythema Migrans in the United States. Antibiotics (Basel, Switzerland), 10(7), . https://doi.org/10.3390/antibiotics10070754
Maloney, Elizabeth L. "Evidence-Based, Patient-Centered Treatment of Erythema Migrans in the United States." Antibiotics (Basel, Switzerland) vol. 10,7 (2021). doi: https://doi.org/10.3390/antibiotics10070754
Maloney EL. Evidence-Based, Patient-Centered Treatment of Erythema Migrans in the United States. Antibiotics (Basel). 2021 Jun 22;10(7). doi: 10.3390/antibiotics10070754. PMID: 34206379; PMCID: PMC8300839.
Copy Download .nbib Format: NLM
Showing 1849 to 1860 of 1876 entries